Colorectal cancer: a disease of the young?

Oncology, The Lancet

doi:10.1016/s1470-2045(17)30202-4

Cited by 48 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We explored similarities in expression using DEGs that were identified in more than 80% of tumors for clustering, and up- and downregulated genes were used separately ( Figures 2A–C ). Among these studied tumors, some of them with similar expression dysregulation features clustered together, such as COAD and READ were clustered together, probably because they both belonged to colorectal cancer (CRC) ( The Lancet Oncology, 2017 ), while UCS, OV, and UCEC, which are uterine and ovarian cancers, clustered together.…”

Section: Resultsmentioning

confidence: 99%

Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data

Zhu

Xing

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide, bringing a significant burden to human health and society. Accurate cancer diagnosis and biomarkers that can be used as robust therapeutic targets are of great importance as they facilitate early and effective therapies. Shared etiology among cancers suggests the existence of pan-cancer biomarkers, performance of which could benefit from the large sample size and the heterogeneity of the studied patients. In this study, we conducted a systematic RNA-seq study of 9,213 tumors and 723 para-cancerous tissue samples of 28 solid tumors from the Cancer Genome Atlas (TCGA) database, and 7,008 normal tissue samples from the Genotype-Tissue Expression (GTEx) database. By differential gene expression analysis, we identified 214 up-regulated and 186 downregulated differentially expressed genes (DEGs) in more than 80% of the studied tumors, respectively, and obtained 20 highly linked up- and downregulated hub genes from them. These markers have rarely been reported in multiple tumors simultaneously. We further constructed pan-cancer diagnostic models to classify tumors and para-cancerous tissues using 10 up-regulated hub genes with an AUC of 0.894. Survival analysis revealed that these hub genes were significantly associated with the overall survival of cancer patients. In addition, drug sensitivity predictions for these hub genes in a variety of tumors obtained several broad-spectrum anti-cancer drugs targeting pan-cancer. Furthermore, we predicted immunotherapy sensitivity for cancers based on tumor mutational burden (TMB) and the expression of immune checkpoint genes (ICGs), providing a theoretical basis for the treatment of tumors. In summary, we identified a set of biomarkers that were differentially expressed in multiple types of cancers, and these biomarkers can be potentially used for diagnosis and used as therapeutic targets.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data

Zhu

Xing

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In this study, we demonstrated the associations between the MMP-11 SNPs and CRC. The incidence of CRC is typically low at ages younger than 50 years but strongly increases with age [ 6 , 42 ]. Although the incidence of early-onset CRC (EOCRC) patients, referring to those individuals younger than 50 years, has been rapidly rising over the last 20 years [ 43 , 44 , 45 ], the median age at diagnosis of CRC is about 70 years in developed countries [ 6 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Matrix Metalloproteinase-11 Polymorphisms on Colorectal Cancer Progression and Clinicopathological Characteristics

Huang

Shiu

et al. 2022

Diagnostics

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide and the most prevalent cancer in Taiwan. The matrix metalloproteinase (MMP)-11 is a proteolytic enzyme of the MMP family which is involved in extracellular matrix degradation and tissue remodeling. In this study, we focused on the associations of MMP-11 single-nucleotide polymorphisms (SNPs) with CRC susceptibility and clinicopathological characteristics. The MMP-11 SNPs rs131451, rs738791, rs2267029, rs738792, and rs28382575 in 479 controls and 479 patients with CRC were analyzed with real-time polymerase chain reaction. We found that the MMP-11 SNP rs738792 “TC + CC” genotype was significantly associated with perineural invasion in colon cancer patients after controlling for clinical parameters [OR (95% CI) = 1.783 (1.074–2.960); p = 0.025]. The MMP-11 rs131451 “TC + CC” genotypic variants were correlated with greater tumor T status [OR (95% CI):1.254 (1.025–1.534); p = 0.028] and perineural invasion [OR (95% CI):1.773 (1.027–3.062); p = 0.040) in male CRC patients. Furthermore, analyses of The Cancer Genome Atlas (TCGA) revealed that MMP-11 levels were upregulated in colorectal carcinoma tissue compared with normal tissues and were correlated with advanced stage, larger tumor sizes, and lymph node metastasis. Moreover, the data from the Genotype-Tissue Expression (GTEx) database exhibited that the MMP-11 rs738792 “CC” and “CT” genotypic variants have higher MMP-11 expression than the “TT” genotype. In conclusion, our results have demonstrated that the MMP-11 SNPs rs738792 and rs131451 may have potential to provide biomarkers to evaluate CRC disease progression, and the MMP-11 rs131451 polymorphism may shed light on sex discrepancy in CRC development and prognosis.

show abstract

“…The occurrence of colorectal cancer is closely related to the growth of polyps, and tumors evolved from polyps are the main cause. The polyps can be divided into three types: proliferative, adenomatous and inflammatory [ 8 , 9 , 10 , 11 ]. The conventional treatment of colorectal cancer is based on surgical resection in the early stage and chemical and/or radiotherapy may be combined according to the condition of the disease.…”

Section: Immunotherapy Of Colorectal Cancermentioning

confidence: 99%

The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer

Chen

Wang

Chen

2021

IJMS

View full text Add to dashboard Cite

Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has various limitations; for instance, it is only suitable for specific patients, the response rate is still low in most cases, etc. Colorectal cancer, lung cancer and pancreatic cancer are known as three major death-causing cancers in most countries. In this review, we discuss immunotherapeutic treatment for these three cancers, and consider the option, prospects and limitations of immunotherapy. The development of immunotherapy should focus on the discovery of biomarkers to screen suitable patients, new targets on tumors, neoadjuvant immunotherapy and the combination of immunotherapy with conventional therapeutic methods. We can expect that immunotherapy potentially will develop as one of the best therapies for patients with advanced cancer or poor responses to traditional methods.

show abstract

Colorectal cancer: a disease of the young?

Cited by 48 publications

References 0 publications

Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data

Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data

The Impact of Matrix Metalloproteinase-11 Polymorphisms on Colorectal Cancer Progression and Clinicopathological Characteristics

The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer

Contact Info

Product

Resources

About